Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study. J of Skin. 2018;2(S1):S10. doi:10.25251/skin.2.supp.10